Nurix Therapeutics (NRIX) Change in Account Payables (2019 - 2026)
Nurix Therapeutics (NRIX) posted quarterly Change in Account Payables of $1.9 million for Q2 2026, up 169.88% year-over-year from $693649.8 in Q2 2025, and up 506.07% quarter-over-quarter from -$461000.0 in Q1 2026.
Powered by 
Analysis
Nurix Therapeutics (NRIX) Change in Account Payables (2019 - 2026) Analysis & Trends
Nurix Therapeutics (NRIX) has reported Change in Account Payables for 8 consecutive years, with $1.9 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Change in Account Payables rose 169.88% year-over-year to $1.9 million; the TTM figure through May 2026 stood at $6.7 million (up 138.86% YoY), while the FY2025 annual figure was -$630000.0, down 112.09% from the prior year.
- Change in Account Payables improved to $1.9 million in Q2 2026 per NRIX's latest filing, from -$461000.0 in the prior quarter.
- Across five years, Change in Account Payables topped out at $7.6 million in Q4 2024 and bottomed at -$3.2 million in Q1 2025.
- Historically, Change in Account Payables has averaged $427166.7 across 5 years, with a median of -$282000.0 in 2022.
- Annual changes were most pronounced in 2023 — Change in Account Payables surged 617.24% — and 2024, when it plunged 332.5%.
- Nurix Therapeutics' Change in Account Payables stood at -$899000.0 in 2022, then soared by 617.24% to $4.6 million in 2023, then surged by 63.12% to $7.6 million in 2024, then tumbled by 60.12% to $3.0 million in 2025, then sank by 38.12% to $1.9 million in 2026.
- Business Quant data shows NRIX's Change in Account Payables at $1.9 million in Q2 2026, -$461000.0 in Q1 2026, and $3.0 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn | -8.00 Mn |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - | 5.03 Mn |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn | 37.53 Mn |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | - |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn | - |
| 10 | Nurix Therapeutics | 2.88 Bn | 2.44 Bn | - | 1.87 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| May 31, 2026 | 1.87 Mn |
| Feb 28, 2026 | -461,000.00 |
| Nov 30, 2025 | 3.03 Mn |
| Aug 31, 2025 | 2.23 Mn |
| May 31, 2025 | -2.68 Mn |
| Feb 28, 2025 | -3.21 Mn |
| Nov 30, 2024 | 7.59 Mn |
| Aug 31, 2024 | 1.10 Mn |
| May 31, 2024 | -2.54 Mn |
| Feb 29, 2024 | -930,000.00 |
| Nov 30, 2023 | 4.65 Mn |
| Aug 31, 2023 | -1.20 Mn |
| May 31, 2023 | -2.24 Mn |
| Feb 28, 2023 | 400,000.00 |
| Nov 30, 2022 | -899,000.00 |
| Aug 31, 2022 | -763,000.00 |
| May 31, 2022 | 1.85 Mn |
| Feb 28, 2022 | -103,000.00 |
| Nov 30, 2021 | 862,000.00 |
| Aug 31, 2021 | -1.39 Mn |